Pharmacokinetics of moxisylyte in healthy volunteers after intracavernous injection of increasing doses

European Journal of Clinical Pharmacology

Volumn 49, Issue 5, 1996, Pages 411-415

  Bressolle, F ^a   Costa, P ^b   Rouzier Panis, R ^b   Marquer, C ^c  

^a UNIV MONTPELLIER   (France)

^b Hopital Gaston Doumergue   (France)

^c Laboratoires Debat   (France)

Author keywords

Adverse events; Healthy volunteers; Intracavernous administration; Metabolism; Moxisylyte; Pharmacokinetics

Indexed keywords

MOXISYLYTE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG URINE LEVEL; HUMAN; HUMAN EXPERIMENT; INTRACAVERNOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER;

EID: 85047678944     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00203788     Document Type: Article

References (16)

1. Krane RJ, Goldstein I, Saenz de Tejada I (1989) Medical progress. Impotence. N Engl J Med 321:1649-1659
2. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB (1994) Impotence and its medical and psychosocial correlates: results of the Massachusetts male aging study. J Urol 151:54-61
3. Costa P, Soulie-Vassal ML, Sarrazin B, Rebillard X, Navratil H, Bali JP (1993) Adrenergic receptors on smooth muscle cells isolated from human penile corpus cavernosum. J Urol 150: 859-863
4. Buvat J, Lemaire A, Buvat-Herbaut M, Marcolin G (1989) Safety of intracavernous injections using an alpha-blocking agent J Urol 141:1364-1367
5. Buvat J, Buvat-Herbaut M, Lemaire A, Marcolin G (1991) Reduced rate of fibrotic nodules of the cavernous bodies following auto-intracavernous injection of moxisylyte compared to papaverine. Int J Impotence Res 3:123-128
6. Costa P, Sarrazin B, Bressolle F, Colson MH, Bondil P, Saudubray F (1993) Efficiency and side-effects of intracavernous injections of moxisylyte in impotent patients: a dose-finding study versus placebo. J Urol 149:301-305
7. Costa P, Bressolle F, Bromet-Petit M, Mosser J, Sarrazin B (1992) Pharmacokinetics of moxisylyte in healthy volunteers after intravenous and oral administration. J Pharm Sci 81:1223-1225
8. Costa P, Bressolle F, Sarrazin B, Mosser J, Galtier M (1993) Pharmacokinetics of moxisylyte in healthy volunteers after intravenous and intracavernous administration. J Pharm Sci 82:729-733
9. Costa P, Bressolle F, Sarrazin B, Mottet N, Rouzier-Panis R, Navratil H, Marquer C (1996) Pharmacokinetics of moxisylyte after intravenous and intracavernous administration. Interest to place a tourniquet. Ther Drug Monit (in press)
10. Costa P, Bressolle F, Sarrazin B, Mosser J, Navratil H, Galtier M (1992) Moxisylyte plasma kinetics in humans after intracavernous administration. Biopharm Drug Disposit 13: 671-679
11. Costa P, Bressolle F, Jarroux E, Sarrazin B, Mosser J, Navratil H, Galtier M (1993) Multiple-dose pharmacokinetics of moxisylyte after oral administration to healthy volunteers. J Pharm Sci 82:968-971
12. Marquer C, Trouvin JH, Lacolle JY, Dupont Ch, Jacquot C (1991) Pharmacokinetics of a prodrug thymoxamine: dose-dependence of the metabolite ratio in healthy subjects. Eur J Drug Metab Pharmacokinet 16:183-188
13. Vollmer KO, Poisson A (1985) Metabolism of thymoxamine. I: Studies with 14C-thymoxamine in man. Eur J Drug Metab Pharmacokinet 10:71-76
14. Duchene P, Bernouillet C, Bromet-Petit M, Mosser J, Feniou C, Gaudin D, Virelizier H (1988) Metabolism of 14C-thymoxamine in rat and man. Xenobiotica 18:919-928
15. Gomeni C, Gomeni R (1987) SIPHAR: An integrated computer system for statistical and pharmacokinetic data analysis. In: Serio A, O'Moore R, Tardini A, Roger FH, eds. Proceedings of the 7th International Congress of Medical Informatics. Rome: European Federation for Medical Informatics, pp 507-516
16. Taburet AM, Steimer JL, Doucet D, Singlas E (1986) Le temps de présence moyen dans l'organisme: un nouveau paramètre pharmacocinétique. Thérapie 41:1-10